What medicines can you not take with Mounjaro — and why it matters

The gastric-emptying effect: why timing and absorption matter

The UK's NHS guidance on tirzepatide explains that Mounjaro slows the rate at which food leaves the stomach, and this mechanism does not stop at food. Any oral medicine you swallow is subject to the same delay. For most drugs taken once daily, the clinical consequence is modest. For medicines where peak concentration and timing are genuinely important (certain antibiotics, immunosuppressants or narrow-therapeutic-index drugs) the shift in absorption can matter enough to warrant a pharmacist's review of when and how you take them.

A common misconception is that this only applies to medicines taken alongside your injection. Because tirzepatide is a once-weekly injection rather than a tablet, people sometimes assume its effects on the gut are similarly brief. In practice, the gastric-emptying slowdown is sustained throughout the week. Any oral drug in your routine is being absorbed in a different environment than it would be without tirzepatide.

The Mounjaro Summary of Product Characteristics (SmPC), available on the eMC, lists the pharmacokinetic interaction data in detail. It is the authoritative reference for your prescriber. If you take any oral medicine regularly, your prescriber will want to know, bring a complete list to your consultation, including over-the-counter medicines and supplements, and our page on what medicines you should not take with Mounjaro is a useful starting point before that conversation. The tirzepatide medicines overview covers the broader clinical picture of what this drug class does in the body.

Insulin and blood-sugar medicines: the most urgent interaction

For people living with type 2 diabetes, the interaction with existing glucose-lowering medicines requires careful prescriber management. The BNF notes that tirzepatide enhances insulin secretion in a glucose-dependent way, meaning the blood-sugar-lowering effect on top of insulin or sulfonylureas (such as glibenclamide, gliclazide or glimepiride) raises the risk of hypoglycaemia. Novo Nordisk and Eli Lilly-class trials both flagged this in their protocols; the Mounjaro SmPC recommends that prescribers consider reducing insulin or sulfonylurea doses before tirzepatide is started.

This is not a reason to avoid Mounjaro if you have type 2 diabetes, tirzepatide is actually licensed for that condition in its own right. It is a reason to have a proper clinical conversation. Abruptly stopping an insulin regimen on your own to avoid the interaction would carry its own serious risks. The adjustment is a prescriber's call, not a patient's. If you currently manage type 2 diabetes and are considering weight management treatment, the Mounjaro overview explains both licences.

Metformin, the most widely prescribed diabetes medicine in the UK, has no clinically meaningful pharmacokinetic interaction with tirzepatide and is commonly continued alongside it. SGLT-2 inhibitors are similarly used in combination in clinical practice, though your prescriber will want to monitor you appropriately.

The oral contraceptive pill: a specifically flagged interaction in the UK

NHS England's guidance on weight-management injections specifically flags this for tirzepatide. Women taking a combined oral contraceptive should add a reliable non-oral method of contraception (such as condoms) during the first four weeks of starting Mounjaro and for four weeks after every dose increase. The concern is that slower gastric emptying could reduce absorption of the contraceptive pill sufficiently to affect its reliability. There is no equivalent evidence-based flag for semaglutide; this appears to be specific to tirzepatide's mechanism.

After those initial four-week windows, if your dose is stable, oral contraceptives are not contra-indicated, but the switch to a transdermal or non-oral method is worth discussing with your GP or a sexual health service regardless, given that weight loss itself can affect fertility. How you take Mounjaro in relation to food and other medicines has practical implications that are worth reading before you start. NHS England also suggests that women on HRT consider transdermal preparations (patches or gels) rather than oral HRT for the same absorption reason.

For cost context, understanding what a complete Mounjaro service actually includes helps when comparing providers. The Mounjaro price changes page explains the UK list price background. A full interaction check is part of any legitimate clinical assessment, not an add-on.

Other medicines worth flagging to your prescriber

Warfarin and other anticoagulants are flagged in the SmPC because altered gastric emptying may affect their absorption or the absorption of vitamin K from food, potentially shifting INR readings. The BNF entry for tirzepatide recommends monitoring anticoagulant effect more closely at treatment initiation and after dose changes. If you are on warfarin, your anticoagulation clinic or GP should know before you begin Mounjaro.

Thyroid hormone replacement (levothyroxine) is worth discussing too. It is typically taken fasting and at a fixed time, and even small changes in absorption can push thyroid levels out of range. There is no absolute contraindication, but TSH monitoring more often than usual in the first months of tirzepatide treatment is sensible. Your prescriber can advise how to sequence the medicines each morning to minimise any absorption overlap.

Medicines with narrow therapeutic windows (anticonvulsants, ciclosporin, certain antiarrhythmics) should always be flagged during a consultation. The interaction with tirzepatide is not always predictable in individuals, and clinical monitoring is the appropriate response. The full medicines interactions page goes into individual drug classes in more depth. You can also read a broader view of weight management options if you are comparing treatment pathways. If you have specific concerns before starting, speaking to our team directly is the fastest way to get a clinical answer.